Achieve Life Sciences Reports 2025 Results, NDA Submission, and PDUFA Date of June 20th, 2026

Achieve Life Sciences reported 2025 financial and operational results, with operating expense of $54.9 million and a net loss of $54.7 million or $1.25 per share. Research and development expense totaled $23 million, up 1% from 2024, while general and administrative expense increased 96% to $31.9 million due to higher employee expenses and commercial launch preparation. Cash and equivalents totaled $36.4 million as of December 31st, 2025.